Implied IHI Analyst Target Price: $155

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares U.S. Medical Devices ETF ( IHI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $155.45 per unit.

START SLIDESHOW:
10 ETFs With Most Upside To Analyst Targets »

With IHI trading at a recent price near $134.06 per unit, that means that analysts see 15.96% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of IHI's underlying holdings with notable upside to their analyst target prices are Accuray Inc ( ARAY), OraSure Technologies Inc. ( OSUR), and Vascular Solutions Inc ( VASC). Although ARAY has traded at a recent price of $4.75/share, the average analyst target is 102.11% higher at $9.60/share. Similarly, OSUR has 40.85% upside from the recent share price of $7.10 if the average analyst target price of $10.00/share is reached, and analysts on average are expecting VASC to reach a target price of $52.25/share, which is 18.62% above the recent price of $44.05. Below is a twelve month price history chart comparing the stock performance of ARAY, OSUR, and VASC:

ARAY, OSUR, and VASC Relative Performance Chart

Below is a summary table of the current analyst target prices discussed above:

Name Symbol Recent Price Avg. Analyst 12-Mo. Target % Upside to Target
iShares U.S. Medical Devices ETF IHI $134.06 $155.45 15.96%
Accuray Inc ARAY $4.75 $9.60 102.11%
OraSure Technologies Inc. OSUR $7.10 $10.00 40.85%
Vascular Solutions Inc VASC $44.05 $52.25 18.62%

Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.

If you liked this article you might like

Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios

2 Momentum Health Care Stocks That Will Continue to Outpace the Industry

12 Best Biotech and Health Care ETFs to Add to Your Portfolio

Noteworthy ETF Outflows: IHI, ABT, TMO, BAX